Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to “Strong-Buy”

Bausch Health Cos (NYSE:BHC) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Several other equities analysts have also recently commented on BHC. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Barclays assumed coverage on shares of Bausch Health Cos in a research note on Monday, December 8th. They issued an “equal weight” rating and a $8.00 target price for the company. Finally, Truist Financial lifted their target price on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Five research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.67.

Bausch Health Cos Price Performance

NYSE BHC opened at $5.89 on Friday. The stock has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $6.71. Bausch Health Cos has a twelve month low of $4.25 and a twelve month high of $8.69. The stock has a market capitalization of $2.18 billion, a PE ratio of 6.07 and a beta of 0.42. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the 1st quarter valued at approximately $68,000. Jones Financial Companies Lllp grew its position in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after acquiring an additional 23,451 shares during the period. Goldman Sachs Group Inc. raised its stake in Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after acquiring an additional 467,270 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Bausch Health Cos by 3.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after acquiring an additional 9,834 shares in the last quarter. Finally, Atria Wealth Solutions Inc. lifted its holdings in shares of Bausch Health Cos by 20.7% during the second quarter. Atria Wealth Solutions Inc. now owns 37,014 shares of the company’s stock valued at $261,000 after acquiring an additional 6,348 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.